



Direct Healthcare Professional Communication

11/02/2018

Human epoetins: new warnings on severe cutaneous adverse reactions

Dear Healthcare Professional,

In agreement the Saudi Food and Drug Authority, Roche Products Saudi Arabia (RPSA) would like to inform you of the risk of severe cutaneous adverse reactions in patients treated with **epoetin beta (RECORMON), and methoxy polyethylene glycol-epoetin beta (MIRCERA)**.

Summary

- Severe cutaneous adverse reactions (SCARs) have been reported in patients treated with epoetins. These included cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) some of which have been fatal.
- Severe cutaneous adverse reactions are considered to be a class effect of all epoetins.
- The reactions have been more severe with long-acting epoetins.
- The frequency of these severe cutaneous reactions could not be calculated but they occur very rarely.
- Patients should be advised of the following signs and symptoms of severe skin reactions when starting treatment with an epoetin product:
 - widespread rash with reddening and blistering of the skin and oral mucosa, eyes, nose, throat, or genital area, which follow flu-like symptoms including fever, tiredness, muscle and joint pain. This often leads to peeling and shedding of the affected skin which looks like a severe burn
- **Patients who develop these signs and symptoms should be instructed to contact their doctor immediately and stop epoetin treatment.**
- If the patient has developed severe cutaneous adverse reactions such as SJS or TEN which is considered to be related to the use of an epoetin, the patient **must never** be given an epoetin again.

Background of the safety concern

Following post-marketing reports of severe cutaneous adverse reactions in particular SJS, TEN and blistering and exfoliative reactions with some epoetins, a detailed analysis of all cases has been performed for all epoetin-containing medicines.

This analysis has revealed that severe cutaneous reactions including SJS and TEN can be considered a class risk for all epoetins. The more severe reactions were reported with long-acting epoetins and included cases with positive dechallenge and positive rechallenge.

The frequency of these severe cutaneous reactions could not be calculated but they occur very rarely.

The product information of all epoetin-containing products, including epoetin beta (RECORMON) and methoxy polyethylene glycol-epoetin beta (MIRCERA) is being updated to reflect the risk of severe cutaneous adverse reactions.

Roche Products Saudi Arabia L.L.C.

P.O. Box 3683 Jeddah 23414
Office No. 5&6 Le Prestige Mall
King Abdulaziz Road, Al Shati District
Jeddah, Kingdom of Saudi Arabia
Commercial Registration: 4030293706
Tel: +966 12 2114600
Fax: +966 12 2114700

شركة روتش بروفاكتس العربية السعودية المحدودة
ص.ب. ٣٦٨٣ جدة ٢٣٤١٤
مكتب رقم ٥ و ٦ لابرستيج مول
طريق الملك عبد العزيز - حي الشاطئ
جدة - المملكة العربية السعودية
رقم السجل التجاري: ٤٠٣٠٢٩٣٧٠٦
هاتف: +٩٦٦ ١٢ ٢١١٤٦٠٠
فاكس: +٩٦٦ ١٢ ٢١١٤٧٠٠



Call for reporting

Please report any suspected adverse reactions associated with the use of epoetin beta and methoxy polyethylene glycol-epoetin beta in accordance with the national requirements via the national spontaneous reporting system, to:

Roche Products Saudi Arabia L.L.C.

Saudi Arabia P.O. Box 3683 Jeddah 23414
Le Prestige Mall
King Abdulaziz Branch Rd
Direct Tel. +966 12211 4618
Mobile : +966 5678 44 692
Email : jeddah.drug_safety@roche.com
Local Safety Responsible: Hassan.linjawi@roche.com
www.roche.com


The National Pharmacovigilance and Drug Safety Centre (NPC)

Land Line: 19999.
Website: <https://ade.sfda.gov.sa>
Email: npc.drug@sfda.gov.sa
Fax: +96612057662.

Yours Sincerely,

Hassan Linjawi


QPPV/Local Safety Responsible



11 FEB 2018

Tamer Elmahallawy


Medical Director



11 Feb 2018

Faisal Al-Samran

Regulatory Director



11 Feb 2018

Roche Products Saudi Arabia L.L.C.

P.O. Box 3683 Jeddah 23414
Office No. 5&6 Le Prestige Mall
King Abdulaziz Road, Al Shati District
Jeddah, Kingdom of Saudi Arabia
Commercial Registration: 4030293706
Tel: +966 12 2114600
Fax: +966 12 2114700

شركة روتش بروفاكتس العربية السعودية المحدودة
ص.ب. 3683 جدة 23414
مكتب رقم 5 و 6 لابريسنيج مول
طريق الملك عبد العزيز - حي الشاطئ
جدة - المملكة العربية السعودية
رقم السجل التجاري: 4030293706
هاتف: +966 12 2114600
فاكس: +966 12 2114700